<?xml version="1.0" encoding="UTF-8"?>
<jcr:root xmlns:sling="http://sling.apache.org/jcr/sling/1.0" xmlns:cq="http://www.day.com/jcr/cq/1.0" xmlns:jcr="http://www.jcp.org/jcr/1.0" xmlns:mix="http://www.jcp.org/jcr/mix/1.0" xmlns:nt="http://www.jcp.org/jcr/nt/1.0" xmlns:rep="internal"
    jcr:mixinTypes="[rep:AccessControllable]"
    jcr:primaryType="cq:Page">
    <rep:policy/>
    <jcr:content
        cq:cugEnabled="true"
        cq:cugLoginPage="/content/aah/paccalvet/en/login.html"
        cq:cugPrincipals="paccalvet"
        cq:lastModified="{Date}2014-04-24T13:47:37.670-04:00"
        cq:lastModifiedBy="churydx"
        cq:lastReplicated="{Date}2014-04-03T01:45:04.026-04:00"
        cq:lastReplicatedBy="admin"
        cq:lastReplicationAction="Activate"
        cq:template="/apps/aah/paccalVet/templates/vetTemplate"
        jcr:isCheckedOut="{Boolean}true"
        jcr:mixinTypes="[mix:versionable]"
        jcr:primaryType="cq:PageContent"
        jcr:title="For Veterinary Oncologists"
        jcr:uuid="777f88d1-6442-4ca4-a57c-95a9a7c0650b"
        sling:resourceType="aah/paccalVet/components/pages/vetTemplate"
        commodityNumber="AAHW-2104 Feb 2014">
        <bottom
            jcr:primaryType="nt:unstructured"
            sling:resourceType="foundation/components/parsys">
            <textpanel
                jcr:created="{Date}2013-11-25T17:45:38.097-05:00"
                jcr:createdBy="kiransr"
                jcr:lastModified="{Date}2014-04-24T13:05:47.833-04:00"
                jcr:lastModifiedBy="churydx"
                jcr:primaryType="nt:unstructured"
                sling:resourceType="aah/paccalVet/components/base/textpanel"
                sectioncopy="&lt;h3>&lt;b>&lt;a name=&quot;risk_info&quot;>&lt;/a>Paccal Vet-CA1 (paclitaxel for injection) Important Risk Information&lt;/b>&lt;/h3>&#xa;&lt;p>&lt;u>Contraindications, warnings and precautions&lt;/u>: Do not use in dogs that have neutropenia (&amp;lt; 2000 cells/μL) or that have concurrent serious infection or in dogs that are pregnant, lactating or intended for breeding. Extravasation during administration can cause focal tissue necrosis and should be avoided. Persons sensitive to retinoids should avoid contact with the drug. Hospital staff and clients should use standard measures for handling cytotoxic drugs and should avoid contact with the drug and the patient’s excretions for the recommended time period. The client should be educated in safe handling of their treated dog’s excretions. More detailed preparation and administration information including special instructions for avoiding human exposure to waste products are supplied in the package insert and the client information sheet.&lt;/p>&#xa;&lt;p>&lt;u>Adverse reactions&lt;/u>: Paclitaxel can cause severe, transient bone marrow suppression within four to seven days of administration and can cause adverse gastrointestinal reactions due to transient gastrointestinal mucosal cell toxicity. In a field study, all the dogs treated (n=168) experienced at least one adverse reaction. Generally, adverse reactions were manageable with appropriate patient monitoring and supportive care. The most frequent adverse reactions were: neutropenia, vomiting, anorexia, diarrhea, and lethargy.&amp;nbsp;Less frequent but still significant adverse reactions included: alopecia, dehydration, dermatitis, hepatopathy, edema, pyrexia and lameness. Other, less frequent adverse reactions included: urine abnormality, pruritus, erythema, anemia, loss of body condition, cutaneous ulceration, thrombocytopenia, neoplasia, polydipsia, conjunctivitis, and death and euthanasia.&lt;/p>&#xa;&lt;p>&amp;nbsp;&lt;/p>&#xa;"/>
        </bottom>
        <center
            jcr:primaryType="nt:unstructured"
            sling:resourceType="foundation/components/parsys">
            <headline
                jcr:created="{Date}2013-12-06T17:20:07.198-05:00"
                jcr:createdBy="kiransr"
                jcr:lastModified="{Date}2014-04-24T13:46:38.408-04:00"
                jcr:lastModifiedBy="churydx"
                jcr:primaryType="nt:unstructured"
                sling:resourceType="aah/paccalVet/components/base/headLine"
                heading="Welcome to Paccal Vet-CA1: a treatment option for canine squamous cell carcinoma and canine mammary carcinoma."/>
            <textpanel
                jcr:created="{Date}2013-12-06T17:22:31.672-05:00"
                jcr:createdBy="kiransr"
                jcr:lastModified="{Date}2014-04-24T13:47:37.667-04:00"
                jcr:lastModifiedBy="churydx"
                jcr:primaryType="nt:unstructured"
                sling:resourceType="aah/paccalVet/components/base/textpanel"
                sectioncopy="&lt;p>&lt;b>Paccal Vet-CA1 is indicated for the treatment of:&lt;/b>&lt;/p>&#xa;&lt;ul>&#xa;&lt;li>Nonresectable stage III, IV or V mammary carcinoma in dogs that have not received previous chemotherapy or radiotherapy&lt;/li>&#xa;&lt;li>Resectable and nonresectable squamous cell carcinoma in dogs that have not received previous chemotherapy or radiotherapy&lt;/li>&#xa;&lt;/ul>&#xa;&lt;p>Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-422.&lt;/p>&#xa;&lt;p>&lt;strong>CAUTION:&lt;/strong> Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. &lt;strong>It is a violation of Federal law to use this product other than as directed in the labeling&lt;/strong>.&lt;/p>&#xa;&lt;p>&lt;strong>See package insert for full&amp;nbsp;&lt;a href=&quot;/content/dam/aah/paccalvet/docs/PaccalVet-CA1%20PAC-2063_PI.pdf&quot; target=&quot;_blank&quot;>Prescribing Information&lt;/a>&lt;/strong>&lt;/p>&#xa;"/>
        </center>
        <image
            jcr:lastModified="{Date}2014-03-26T19:50:51.242-04:00"
            jcr:lastModifiedBy="churydx"
            jcr:primaryType="nt:unstructured"
            imageRotate="0"/>
    </jcr:content>
    <about-paccalvet/>
    <Cremophor-Free/>
    <taxanes-in-humans/>
    <resources/>
    <user-report/>
    <changepassword/>
    <my-profile/>
</jcr:root>
